AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (NASDAQ: APEN), a medical technology company primarily focused on the design, development and commercialization of innovative medical devices that can be used for the treatment of obesity, today announced the closing of its previously announced public offering of 6,542,453 shares of common stock, including 853,363 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds from the offering at a public offering price of $5.50 per share, before underwriting discounts and commissions and offering expenses, were approximately $36 million.
Craig-Hallum Capital Group LLC and Roth Capital Partners acted as joint book-running managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on July 19, 2017. A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website, located at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained from Craig-Hallum Capital Group LLC at 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets, by telephone at 612-334-6300, or by e-mail at prospectus@chlm.com, or alternatively from Roth Capital Partners, LLC, Attention: Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, by telephone at 800-678-9147, or by email at rothecm@roth.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 80 countries today.
